Literature DB >> 24613979

Neuropsychiatric symptoms in the prodromal stages of dementia.

Florindo Stella1, Márcia Radanovic, Márcio L F Balthazar, Paulo R Canineu, Leonardo C de Souza, Orestes V Forlenza.   

Abstract

PURPOSE OF REVIEW: To critically discuss the neuropsychiatric symptoms in the prodromal stages of dementia in order to improve the early clinical diagnosis of cognitive and functional deterioration. RECENT
FINDINGS: Current criteria for cognitive syndrome, including Alzheimer's disease, comprise the neuropsychiatric symptoms in addition to cognitive and functional decline. Although there is growing evidence that neuropsychiatric symptoms may precede the prodromal stages of dementia, these manifestations have received less attention than traditional clinical hallmarks such as cognitive and functional deterioration. Depression, anxiety, apathy, irritability, agitation, sleep disorders, among other symptoms, have been hypothesized to represent a prodromal stage of dementia or, at least, they increase the risk for conversion from minor neurocognitive disorder to major neurocognitive disorder. Longitudinal investigations have provided increased evidence of progression to dementia in individuals with minor neurocognitive disorder when neuropsychiatric symptoms also were present.
SUMMARY: Although neuropsychiatric symptoms are strongly associated with a higher risk of cognitive and functional deterioration, frequently the clinician does not acknowledge these conditions as increasing the risk of dementia. When the clinician accurately diagnoses neuropsychiatric symptoms in the prodromal stage of dementia, he could early establish appropriate treatment and, may be, delay the beginning of clinical and functional deterioration.

Entities:  

Mesh:

Year:  2014        PMID: 24613979     DOI: 10.1097/YCO.0000000000000050

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  16 in total

1.  Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.

Authors:  Fabienne A Biétry; Alena M Pfeil; Oliver Reich; Matthias Schwenkglenks; Christoph R Meier
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

2.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.

Authors:  Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

3.  Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.

Authors:  Patrick Imfeld; Michael Bodmer; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

4.  Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment.

Authors:  Nicholas D David; Feng Lin; Anton P Porsteinsson
Journal:  Am J Geriatr Psychiatry       Date:  2015-06-27       Impact factor: 4.105

5.  Characterisation of Physical Frailty and Associated Physical and Functional Impairments in Mild Cognitive Impairment.

Authors:  Ma Shwe Zin Nyunt; Chang Yuan Soh; Qi Gao; Xinyi Gwee; Audrey S L Ling; Wee Shiong Lim; Tih Shih Lee; Philip L K Yap; Keng Bee Yap; Tze Pin Ng
Journal:  Front Med (Lausanne)       Date:  2017-12-18

6.  Neuropsychiatric Symptoms in Patients with the Main Etiological Types of Mild Neurocognitive Disorders: A Hospital-Based Case-Control Study.

Authors:  Oleg A Levada; Nataliya V Cherednichenko; Alexandra S Troyan
Journal:  Front Psychiatry       Date:  2017-05-04       Impact factor: 4.157

7.  Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study.

Authors:  Shelly L Gray; Sascha Dublin; Onchee Yu; Rod Walker; Melissa Anderson; Rebecca A Hubbard; Paul K Crane; Eric B Larson
Journal:  BMJ       Date:  2016-02-02

Review 8.  Mild cognitive impairment in Parkinson's disease: a distinct clinical entity?

Authors:  Ming-Ching Wen; Ling Ling Chan; Louis C S Tan; Eng King Tan
Journal:  Transl Neurodegener       Date:  2017-09-13       Impact factor: 8.014

9.  Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice.

Authors:  Peng-Hui Ai; Si Chen; Xian-Dong Liu; Xiao-Na Zhu; Yuan-Bo Pan; Dong-Fu Feng; Shengdi Chen; Nan-Jie Xu; Suya Sun
Journal:  Transl Neurodegener       Date:  2020-05-12       Impact factor: 8.014

10.  Lifetime affective problems and later-life cognitive state: Over 50 years of follow-up in a British birth cohort study.

Authors:  Sarah-Naomi James; Daniel Davis; Celia O'Hare; Nikhil Sharma; Amber John; Darya Gaysina; Rebecca Hardy; Diana Kuh; Marcus Richards
Journal:  J Affect Disord       Date:  2018-07-30       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.